Portal de Periódicos da CAPES

Consensus statement for the treatment of infantile haemangiomas with propranolol

2017; Wiley; Volume: 58; Issue: 2 Linguagem: Inglês

10.1111/ajd.12600

1440-0960

Sarah L. Smithson, Marius Rademaker, Susan Adams, Stuart Bade, Philip Bekhor, Samantha Davidson, Amanda Dore, Catherine J. Drummond, Gayle Fischer, Alexander Gin, Claire Grills, Anne Halbert, Zerina Lokmic‐Tomkins, Emma McCahon, Vanessa Morgan, Dédée F. Murrell, David Orchard, Anthony Penington, Diana Purvis, John Relic, Susan J. Robertson, Aaron Robinson, Laura Scardamaglia, John Su, Swee T. Tan, Orli Wargon, Lachlan Warren, Li‐Chuen Wong, Tania Zappala, Roderic J Phillips,

Parvovirus B19 Infection Studies

Although most infantile haemangiomas do not require treatment due to a natural history of spontaneous involution, some require early intervention. The Australasian Vascular Anomalies Network and the Australasian Paediatric Dermatology Network have developed a consensus statement for the treatment of infantile haemangiomas with oral propranolol. Infants with haemangiomas that are life threatening, at risk of ulceration, or at risk of causing a significant functional impairment, psychological impact or physical deformity should be treated early with oral propranolol. Oral propranolol is safe and effective and in most healthy infants oral propranolol can be started in an outpatient setting.